Posts

ADA 2026: Zealand and Roche pitch amylin agonist petrelintide as best‑in‑class obesity monotherapy

on
azealnd Sources: ADA: Roche, Zealand make tolerability case for petrelintide Roche announces positive Phase II results for petrelintide ... Company Announcement - Markets data Roche enters into an exclusive collaboration & licensing agreement ... Obesity - BioSpace Company announcement Petrelintide - Pipeline - Zealand Pharma H1 2025 Presentation Zealand Pharma and Roche to advance obesity drug to Phase 3 Roche and Zealand's Phase II obesity trial divides analyst opinion Obesity biotech Zealand seeks partners to 'take therapies directly to ... Zealand Pharma H1 2025 presentation: Revenue surges on Roche partnership, obesity pipeline advances Roche Makes Another Obesity Play With Potential $5.3B Amylin ... Roche expands obesity pipeline, signs $5.3 billion deal for ... Roche pushes ahead with late-comer strategy in obesity

Busy FDA gives rare disease sector complementary pathways, unanswered questions – 2026 snapshot

on

ADA: Metsera asset data support Pfizer’s entry point into obesity market

on

Roche Launches Up to $2.3B Blood‑Cancer Bet Around Nurix’s BTK Degrader Bexobrutideg

on

Incyte acquires Vega Therapeutics for up to $2B to add late‑phase bleeding‑disorder asset VGA039

on

Roche's incretin GLP‑1/GIP shot shows promise in mid‑stage trial for type 1 diabetes

on

Takeda expects $2.5B hit after Amitiza antitrust verdict, with plans to appeal

on

AstraZeneca CEO says AI is reshaping drug development and helping boost the odds of success

on

Otsuka touts new IgAN evidence as it seeks full approval for Voyxact

on

Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal

on

Lilly and Novo Face Off at ADA 2026 as Others Seek to Compete in Obesity

on

Lupin Receives U.S. FDA Approval for Ranluspec™ (ranibizumab) Injection: Interchangeable Biosimilar for Eye Diseases Now Cleared in the U.S.

on

Supreme Court sides with Hikma in 'skinny label' case

on